Trial · NCT07262060
Improving Preterm Kidney Outcomes With Caffeine
NCT07262060, Phase 2, Recruiting, University of Wisconsin, Madison
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Improving Preterm Kidney Outcomes With Caffeine. Trials, record NCT07262060. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07262060
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Improving Preterm Kidney Outcomes With Caffeine
- NCT number
- NCT07262060
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 114 participants, estimated
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Kidney Injury, Pre-Term
- Interventions
- Caffeine citrate, Placebo
- First posted
- 2025-12-03
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants with Improvement in Kidney Oxygenation | Up to 3 hours post-intervention (Between days 1 and 17) | In the 3 hours after receiving the intervention or placebo, participants have kidney oxygenation monitored. Improvement in oxygenation is defined as having 30 minutes where at least 90 percent of measured values are at least 50 percent. |
| Secondary | Number of Days of Acute Kidney Injury (AKI) | 14 days after intervention | AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) foundation. Outcome is measured for the 14 days after intervention. |
| Secondary | Proportion of Participants with a Sustained Decrease in Cerebral Oxygenation | up to 3 hours post-intervention (Between days 1 and 17) | In the 3 hours after receiving the intervention or placebo, participants have cerebral oxygenation monitored. A sustained decrease in cerebral oxygenation is defined as less than 60 percent oxygenation for at least 60 minutes. |
| Other | Change in Urinary Biomarker Concentrations | baseline, day 17 | |
| Other | Rates of Brain Injury | up to 6 months | Rates of Brain injury (Periventricular Leukomalacia (PVL) or Interventricular hemorrhage (IVH) on term corrected brain imaging prior to discharge in participants receiving additional caffeine compared to those receiving placebo. |
| Other | Rates of Abnormal General Movement Assessment (GMA) | up to 6 months | Rates of abnormal GMA prior to discharge in participants receiving additional caffeine compared to those receiving placebo. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HD116793 | Optimizing Caffeine Therapy for Hypoxia in Preterm Neonates: A Randomized Trial Assessing Efficacy, Acute Kidney and Brain Injury, Safety, and Pharmacokinetics | HARER, MATTHEW | UNIVERSITY OF WISCONSIN-MADISON | EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07262060
GET https://conductscience.org/api/trials/v1/NCT07262060/registered